Parmax Pharma Gains 1.90%: 2 Key Milestones Mark a Week of Strong Momentum

27 July 2026: Strong Start to the Week

Parmax Pharma began the week positively, closing at Rs.104.87, a 1.98% increase from the previous Friday’s close of Rs.102.83. This outpaced the Sensex’s 1.05% gain to 36,207.16 points, signalling early investor interest. The volume was robust at 109,947 shares, indicating healthy participation. The broader market optimism likely supported this initial advance.

28 July 2026: Gains Amid Market Weakness

Despite the Sensex slipping 0.14% to 36,155.32, Parmax Pharma extended its rally, rising 1.99% to Rs.106.96. The stock’s resilience against a declining benchmark suggests selective buying interest. However, volume dropped sharply to 10,892 shares, which may indicate cautious trading or profit booking by short-term participants.

29 July 2026: Continued Momentum with Sector Support

The stock maintained its upward trajectory, closing at Rs.109.09 (+1.99%) as the Sensex rebounded 1.02% to 36,524.95. The volume was modest at 4,726 shares but represented 100% delivery, signalling genuine accumulation. This day’s gains set the stage for the significant price action on 30 July.

30 July 2026: New 52-Week and All-Time Highs

Parmax Pharma Ltd reached a landmark by hitting a new 52-week and all-time high of Rs.111.27 on 30 July 2026. The stock opened at this level and maintained it throughout the session, closing with a 2.00% gain. This marked the culmination of a four-day winning streak that delivered an 8.21% return. The stock outperformed its sector peers by 1.9% and the Sensex, which declined 0.15% that day, underscoring its relative strength.

Technical indicators strongly supported this bullish momentum. The stock traded above all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), with weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory indicators signalling sustained upward trends. However, the Relative Strength Index (RSI) remained bearish on weekly and monthly charts, suggesting caution due to potential overbought conditions.

Despite the positive price action, Parmax Pharma remains a micro-cap with a Mojo Score of 31.0 and a current Mojo Grade of Sell, upgraded from Strong Sell earlier in June 2026. The company’s valuation metrics reflect ongoing losses, with negative P/E and EV multiples, and a below-average quality grade due to declining sales and EBIT over five years. Nonetheless, the stock’s recent price performance highlights strong market interest and momentum.

31 July 2026: Profit Taking and Weekly Close

The stock retreated 1.99% to close at Rs.104.78 on the final trading day of the week, with volume rising to 36,319 shares. This pullback from the all-time high reflects profit-taking after the strong rally. Meanwhile, the Sensex continued its upward trend, gaining 0.39% to 36,684.83. The weekly close price still represents a 1.90% gain over the week, though the stock underperformed the Sensex’s 2.39% rise.

Daily Price Comparison: Parmax Pharma vs Sensex

Key Takeaways

Positive Signals: Parmax Pharma’s achievement of a new 52-week and all-time high at Rs.111.27 on 30 July 2026 highlights strong short-term momentum and investor interest. The stock’s consistent gains over four consecutive days, supported by bullish technical indicators and outperformance relative to the Sensex and sector peers, underscore its resilience. The upgrade in Mojo Grade from Strong Sell to Sell reflects improving market sentiment despite ongoing financial challenges.

Cautionary Notes: Despite price strength, the stock remains a micro-cap with below-average quality metrics, including declining sales and EBIT over five years and negative valuation multiples. The bearish RSI on weekly and monthly charts suggests potential overbought conditions, warranting caution. The weekly close retreat from the peak indicates profit-taking pressure. Additionally, the stock’s weekly gain of 1.90% lagged the Sensex’s 2.39% rise, signalling relative underperformance over the full week.

Conclusion

Parmax Pharma Ltd’s week was defined by a significant milestone as it reached a new 52-week and all-time high of Rs.111.27 on 30 July 2026, reflecting strong momentum and technical strength. While the stock’s weekly gain of 1.90% was modest and slightly behind the Sensex’s 2.39% advance, the achievement of this peak amid a mixed market environment is notable. Investors should weigh the positive price action and technical signals against the company’s ongoing financial challenges and valuation concerns. The stock’s micro-cap status and volatile price history suggest that monitoring fundamental developments alongside technical trends will remain essential going forward.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today